Drug intelligence / Profile preview

APZ103

Development stage: Preclinical
Lead developer: Foshan Ampze Biopharma
Modality: Small Molecules

Overview

APZ103 is an innovative anti-tumor drug candidate currently in early development by Foshan Ampze Biopharma (also known as Annpobio). The drug is part of the company's transition from biosimilar development toward novel innovative therapeutics. While the specific molecular target and modality have not been officially disclosed, the company's core expertise lies in recombinant protein and antibody development, suggesting APZ103 is likely a biologic agent intended for oncology indications. As of 2024, the asset is positioned in the early development (preclinical) stage of the sponsor's pipeline.

Other names: APZ103APZ-103APZ 103

Beyond the preview

Go deeper on APZ103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APZ103.

Explore the full profile